Curatis Holding AG (XSWX:CURN) YoY EBITDA Growth: 96.89% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:CURN Curatis Holding AG XSWX:CURN
33 GF Score
Price CHF18.55
! 4 Warning Signs
View Full Analysis

What is Curatis Holding AG YoY EBITDA Growth?

Curatis Holding AG XSWX:CURN -4.38% 33 YoY EBITDA Growth is 96.89% as of Dec. 2025. GuruFocus rates XSWX:CURN with a GF Score™ of 33/100. The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Curatis Holding AG's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 96.89%.

Curatis Holding AG's EBITDA per Share for the six months ended in Dec. 2025 was CHF-0.01.

Curatis Holding AG YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Curatis Holding AG's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curatis Holding AG YoY EBITDA Growth Chart

Curatis Holding AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
0.00 -6,647.68 43.98 98.91 84.83

Curatis Holding AG Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.76 87.65 99.85 71.21 96.89
XSWX:CURN
33GF Score
Curatis Holding AG XSWX:CURN
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curatis Holding AG YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Curatis Holding AG's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.226--1.49)/ | -1.49 |
=84.83 %

Curatis Holding AG's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(-0.006--0.193)/ | -0.193 |
=96.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 96.89% mean?
Curatis Holding AG (XSWX:CURN) has a YoY EBITDA Growth of 96.89% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Curatis Holding AG and its competitors.
Is Curatis Holding AG's YoY EBITDA Growth too high?
Curatis Holding AG's current YoY EBITDA Growth is 96.89%. Overall, Curatis Holding AG has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Curatis Holding AG's YoY EBITDA Growth compare to ZTS and UTHR?
Curatis Holding AG's YoY EBITDA Growth of 96.89% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Curatis Holding AG and its competitors. Curatis Holding AG's current YoY EBITDA Growth is 96.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curatis Holding AG stock overvalued right now?
Curatis Holding AG (XSWX:CURN) has a current YoY EBITDA Growth of 96.89%. The current YoY EBITDA Growth is 96.89%. Curatis Holding AG's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Curatis Holding AG (XSWX:CURN), the current YoY EBITDA Growth is 96.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curatis Holding AG Business Description

Other Exchanges CURNz:UK0QNS:UK26U:Germany
Address Weierweg 7, Liestal, CHE, CH-4410
Curatis Holding AG is a specialty pharmaceutical Company with two-pillar. On one hand, the Company trades and distributes specialty medicines in the rare disease and specialty medicines space i.e. acquires, licenses, distributes and promotes pharmaceutical products for the treatment and/or prevention of rare and specialty diseases in Switzerland. On the other hand, it is a drug development Company with a pipeline of product candidates, also predominantly in the orphan drug space.
33GF Score

Get the complete analysis for XSWX:CURN

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF18.55
Price